Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 5/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24111252 | 0.95 | GLP1R (0.51) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL21349162 | 0.92 | GLP1R (0.51) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL12981270 | 0.90 | GLP1R (0.56) | GLP1RSIRT6SIRT1TLR2SIRT5 | |
| SCHEMBL21166941 | 0.89 | GLP1R (0.52) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL13475034 | 0.87 | GLP1R (0.56) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL3484885 | 0.86 | GLP1R (0.54) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL4517738 | 0.86 | GLP1R (0.54) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL16326833 | 0.85 | GLP1R (0.53) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL17772689 | 0.84 | GLP1R (0.62) | GLP1RSIRT6SIRT1TLR2NMT2 | |
| SCHEMBL24139980 | 0.83 | GLP1R (0.40) | GLP1RSIRT6SIRT1TLR2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2022-12-29 | — | — | US | disclosed |
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-12-07 | — | — | US | disclosed |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | ADOCIA (FR) | 2021-09-28 | — | — | US | disclosed |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-10-31 | — | — | US | disclosed |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | GLP1R 11/4885SIRT6 2014/4885SIRT1 1911/4885 |
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GIPR, GLP1R | GLP1R 3/4885SIRT6 985/4885SIRT1 2012/4885 |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GIPR, GLP1R | GLP1R 3/4885SIRT6 1153/4885SIRT1 2038/4885 |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | IAPP, GLP1R, INSR | GLP1R 2/4885SIRT6 3921/4885SIRT1 3534/4885 |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | GCG, GLP1R, GHSR | GLP1R 2/4885SIRT6 1059/4885SIRT1 1568/4885 |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | GLP1R 31/4885SIRT6 2471/4885SIRT1 3889/4885 |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | GLP1R 3/4885SIRT6 3612/4885SIRT1 3531/4885 |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | GLP1R 31/4885SIRT6 2471/4885SIRT1 3889/4885 |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GLP1R, INSR | GLP1R 2/4885SIRT6 3921/4885SIRT1 3534/4885 |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, GCGR | GLP1R 2/4885SIRT6 671/4885SIRT1 1109/4885 |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, GCG, HBB | GLP1R 16/4885SIRT6 1455/4885SIRT1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.